Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Abroad (travel likely)RecruitingPHASE2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation · Advanced PDTC or ATC With NRAS Mutation
Locations
- Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China